Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Amit Sanyal, MD: A Clinician’s Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Apr

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Amit Sanyal, MD: A Clinician’s Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Fullerene Cream vs Trolamine Cream in Reducing Acute Radiation Dermatitis From Radiation Therapy for Head and Neck Cancer

Skin Fluorescent Imaging Shows High Sensitivity, Specificity for Discriminating Melanoma Lesions

NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient

Tanning Bed Exposure and Melanoma Risks

AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation